{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:16:27Z","timestamp":1785838587833,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bulcan.2022.06.011","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T05:37:41Z","timestamp":1663047461000},"page":"1245-1261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gestion pratique des inhibiteurs de PARP\u00a0: Un consensus national DELPHI"],"prefix":"10.1016","volume":"109","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Selle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Angelergues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paule","family":"Augereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Dielenseger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Follana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Marjollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2022.06.011_bib0240","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/annonc\/mdq322","article-title":"A review of PARP inhibitors: from bench to bedside","volume":"22","author":"Underhill","year":"2011","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2022.06.011_bib0245","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2022.06.011_bib0250","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2022.06.011_bib0255","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2\u00a0mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3\u00a0trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.06.011_bib0260","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.bulcan.2022.06.011_bib0265","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bulcan.2022.06.011_bib0270","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2022.06.011_bib0275","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2022.06.011_bib0280","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ijgc-2019-000623","article-title":"Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA -mutated, high-grade ovarian cancer, and an update on safety","volume":"29","author":"Kristeleit","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"10106","key":"10.1016\/j.bulcan.2022.06.011_bib0285","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bulcan.2022.06.011_bib0290","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2022.06.011_bib0295","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bulcan.2022.06.011_bib0300","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0305","unstructured":"European Medecines Agency (EMA). Lynparza: EPAR\u00a0\u2013\u00a0Product Information (PDF) [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2022.06.011_bib0310","unstructured":"European Medecines Agency (EMA). Zejula: EPAR\u00a0\u2013\u00a0Product Information (PDF) [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zejula-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2022.06.011_bib0315","unstructured":"European Medecines Agency (EMA). Rubraca: EPAR\u00a0\u2013\u00a0Product Information (PDF) [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rubraca-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2022.06.011_bib0320","unstructured":"European Medecines Agency (EMA). Talzenna: EPAR\u00a0\u2013\u00a0Product Information (PDF) [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf."},{"issue":"1","key":"10.1016\/j.bulcan.2022.06.011_bib0325","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.06.011_bib0330","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14740338.2017.1325871","article-title":"The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer","volume":"16","author":"Lorusso","year":"2017","journal-title":"Expert Opinion on Drug Safety"},{"issue":"6","key":"10.1016\/j.bulcan.2022.06.011_bib0335","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/AOG.0000000000004170","article-title":"Adherence to oral anticancer therapeutics in the gynecologic oncology population","volume":"136","author":"Watson","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.bulcan.2022.06.011_bib0340","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1\u00a0study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.06.011_bib0345","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2022.06.011_bib0350","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0355","unstructured":"National Comprehensive Cancer Network (NCCN). Supportive Care [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.nccn.org\/guidelines\/category_3."},{"issue":"2","key":"10.1016\/j.bulcan.2022.06.011_bib0360","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2020.08.016","article-title":"Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer","volume":"159","author":"Eakin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0365","unstructured":"Association Francophone des Soins de Support (AFSOS). Liste compl\u00e8te des r\u00e9f\u00e9rentiels par ordre alphab\u00e9tique [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.afsos.org\/liste-complete-referentiels\/."},{"issue":"25","key":"10.1016\/j.bulcan.2022.06.011_bib0370","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","article-title":"American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review\u2013Based Consensus Methodology","volume":"30","author":"Loblaw","year":"2012","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.bulcan.2022.06.011_bib0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12094-016-1508-y","article-title":"Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study","volume":"19","author":"Gavila","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0380","unstructured":"HAS (Haute Autorit\u00e9 de Sant\u00e9). Guide m\u00e9thodologique. \u00c9laboration de recommandations de bonne pratique. M\u00e9thode \u00ab\u00a0Recommandations pour la pratique clinique\u00a0\u00bb [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2011-01\/guide_methodologique_consensus_formalise.pdf."},{"key":"10.1016\/j.bulcan.2022.06.011_bib0385","unstructured":"Hsu CC, Sandford BA. The Delphi Technique: Making Sense of Consensus. [cit\u00e9 22\u00a0juin 2022]\u00a0; Disponible sur\u00a0: https:\/\/scholarworks.umass.edu\/pare\/vol12\/iss1\/10\/."},{"issue":"4","key":"10.1016\/j.bulcan.2022.06.011_bib0390","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0395","article-title":"The Delphi Method Research Strategy in Studies of Information Systems","volume":"37","author":"Skinner","year":"2015","journal-title":"CAIS [Internet]"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0400","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-016-0257-x","article-title":"How to use the nominal group and Delphi techniques","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm [Internet]"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0405","unstructured":"Institut National du Cancer (INCa). Le Plan cancer 2009\u20132013 [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.e-cancer.fr\/Institut-national-du-cancer\/Strategie-de-lutte-contre-les-cancers-en-France\/Les-Plans-cancer\/Le-Plan-cancer-2009-2013."},{"issue":"2","key":"10.1016\/j.bulcan.2022.06.011_bib0410","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2022.06.011_bib0415","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2022.06.011_bib0420","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2022.06.011_bib0425","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1\u00a0trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2022.06.011_bib0430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JOP.18.00705","article-title":"Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer","volume":"15","author":"Shammo","year":"2019","journal-title":"JOP"},{"issue":"2","key":"10.1016\/j.bulcan.2022.06.011_bib0435","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2022.06.011_bib0440","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0445","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.06.011_bib0450","first-page":"190","article-title":"An approach to vertigo in general practice","volume":"45","author":"Dommaraju","year":"2016","journal-title":"Aust Fam Physician"},{"issue":"5","key":"10.1016\/j.bulcan.2022.06.011_bib0455","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.otc.2012.06.001","article-title":"Evidence-based practice: management of vertigo","volume":"45","author":"Nguyen-Huynh","year":"2012","journal-title":"Otolaryngol Clin North Am"},{"issue":"3","key":"10.1016\/j.bulcan.2022.06.011_bib0460","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","article-title":"Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas","volume":"150","author":"Bi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2022.06.011_bib0465","unstructured":"Institut National du Cancer (INCa). Pr\u00e9vention et gestion des effets ind\u00e9sirables des anticanc\u00e9reux [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Medicaments\/Prevention-suivi-et-gestion-des-effets-indesirables\/Referentiels-integraux."},{"key":"10.1016\/j.bulcan.2022.06.011_bib0235","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. Minist\u00e8re des Solidarit\u00e9s, de l\u2019Autonomie et des personnes handicap\u00e9es. Exp\u00e9rimenter et innover pour mieux soigner. Organisation et financement du syst\u00e8me de sant\u00e9 [Internet]. [Cit\u00e9 27\u00a0juin 2022]. Disponible sur\u00a0: https:\/\/solidarites-sante.gouv.fr\/systeme-de-sante-et-medico-social\/parcours-des-patients-et-des-usagers\/article-51-lfss-2018-innovations-organisationnelles-pour-la-transformation-du\/article-51?TSPD_101_R0=087dc22938ab2000d7a4bef38a435ca678e860d9caaf4695ce88cd86e355ac34924d8af67a27213508e316147c143000b7e37ac105c85038c1be4203cb23cb486640237ae33e48123e8abaa0f2a3a71954142455a4e19ddd6274d7e121e8b043."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:27Z","timestamp":1757792187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0007455122003009"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.06.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gestion pratique des inhibiteurs de PARP\u00a0: Un consensus national DELPHI","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}